Summary for Tradename: EVISTA
Clinical Trials for: EVISTA
Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis
Status: Completed Condition: Osteoporosis, Postmenopausal
Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women
Status: Recruiting Condition: Negative Symptoms of Schizophrenia in Post-menopausal Women.
Long Term Effects of Raloxifene Treatment on Bone Quality
Status: Completed Condition: Osteoporosis, Post-Menopausal
Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer
Status: Active, not recruiting Condition: Prostate Cancer; Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Stage IV Prostate Cancer
Cognition in the Study of Tamoxifen and Raloxifene
Status: Completed Condition: Cognition; Aging
Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis
Status: Completed Condition: Postmenopausal Osteoporosis; Compliance
Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome
Status: Recruiting Condition: Polycystic Ovary Syndrome
Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen
Status: Completed Condition: Vasomotor Symptoms; Endometrial Safety
Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease
Status: Completed Condition: Breast Cancer
The Safety and Effectiveness of Surgery With or Without Raloxifene for the Treatment of Pelvic Pain Caused by Endometriosis
Status: Completed Condition: Endometriosis; Pelvic Pain
Courtesy of ClinicalTrials.org
See more clinical trials for this drug
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Type||RLD||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|TABLET;ORAL||020815||Dec 9, 1997||RX||Yes||<disabled>||<disabled>|
|TABLET;ORAL||020815||Dec 9, 1997||RX||Yes||5,478,847||<disabled>||Y||<disabled>|
|TABLET;ORAL||020815||Dec 9, 1997||RX||Yes||5,811,120||<disabled>||<disabled>|
|TABLET;ORAL||020815||Dec 9, 1997||RX||Yes||5,972,383||<disabled>||<disabled>|
|This preview shows a limited data set|
Complete access is available with a Subscription
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639